Diovan remains the strongest selling of Novartis’ products; however revenue has already started to decline in markets such as Brazil, Canada and Spain.
In order to counter balance the impact of increase generics competition, Novartis has launched new line extensions – e.g. Co-Diovan and Exforge. The latter has seen an increase in sales by 36 per cent to $317m in the last quarter.
Further efforts to boost sales and defend against generics competition has seen Novartis shift focus onto Rasilez, a renin inhibitor-based antihypertensive which grew 47 per cent to $305m in the first three quarters of 2011.